Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Essen – page 52

989 clinical trials in Essen, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Essen at a glance
989
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

989 trials in Essen

Open in trial search

Acute lymphocytic leukaemia+6

Not recruiting

Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Thalassaemia

Not recruiting

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan and Ipilimumab for Men with Very High-Risk Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Universitaetsklinikum Essen AöR

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Malignant melanoma stage III

Not recruiting

Study on L19IL2 and L19TNF Treatment Before Surgery for Patients with Advanced Melanoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa
  • Sponsor:Philogen S.p.A.

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Anal cancer stage II+1

Not recruiting

Study on Durvalumab with Radiochemotherapy for Patients with Locally-Advanced Anal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Goethe University Frankfurt

Gastrooesophageal cancer+1

Not recruiting

Study on Organ Preservation for Early Stage Esophageal Cancer Using Durvalumab and Chemoradiation for Patients Eligible for Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Adverse drug reaction+1

Not recruiting

Study on Methoxsalen for Treating Immune-Related Side Effects in Patients After Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Methoxsalen
  • Sponsor:Medical Center - University Of Freiburg

Renal failure

Not recruiting

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rmc-035
  • Sponsor:Guard Therapeutics International AB (publ)

Gastrointestinal stromal tumour

Not recruiting

Study of IDRX-42 for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:[4-(Methyl-1H-Pyrazol-4-Yl)-Benzyl] (6[7-(3-Pyrrolidin-1-Yl-Propoxy)-Imidazo[1,2-A] Pyridin-3-Yl]-Pyrimidin-4-Yl]-Amine
  • Sponsor:Idrx Inc.

Duchenne muscular dystrophy+1

Not recruiting

Study on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Essen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic colorectal cancer, breast cancer, and lymphoma treatments. Studies evaluate novel therapeutic combinations and targeted approaches for various cancer types.

  • HER2-positive breast cancer therapies
  • Diffuse Large B-Cell Lymphoma treatments
  • Metastatic prostate cancer interventions

Research includes evaluation of new drug combinations and immunotherapy approaches.

02 Respiratory Medicine

Studies examining preventive treatments for respiratory syncytial virus and related infections. Research focuses on vaccine development and immune response in different age groups.

  • RSV vaccine efficacy studies
  • Human Metapneumovirus research
  • Pneumococcal disease prevention

Emphasis on protecting vulnerable populations including older adults and at-risk individuals.

03 Neurological Disorders

Clinical research addressing Alzheimer's disease and acute cerebral ischemic stroke. Investigations into novel therapeutic approaches and diagnostic tools.

  • Early-stage Alzheimer's treatment
  • Stroke recovery interventions
  • Spinal muscular atrophy therapies

Focus on improving patient outcomes through innovative treatment strategies.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.